Table 4. Association between TAS2R haplotypes/genotypes and colorectal adenoma risk (N=2102).
| All | Japanese Americans | Whites | Native Hawaiians | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||||||||
| Controls n (%) | Case n (%) | OR (95%, CI) | Ppart-adj | Pfull-adj | Controls n (%) | Case n (%) | OR (95%, CI) | Ppart-adj | Pfull-adj | Controls n (%) | Case n (%) | OR (95%, CI) | Ppart-adj | Pfull-adj | Controls n (%) | Case n (%) | OR (95%, CI) | Ppart-adj | Pfull-adj | Race/Ethnicity-by-Gene Interaction† | ||
|
| ||||||||||||||||||||||
| Ppart-adj | Pfull-adj | |||||||||||||||||||||
| TAS2R38 | ||||||||||||||||||||||
| AVI/AVI | 288 (25.6) | 211 (24.5) | 1.00 (referent) | 82 (21.2) | 54 (18.6) | 1.00 (referent) | 182 (35.7) | 130 (33.8) | 1.00 (referent) | 24 (10.6) | 27 (14.4) | 1.00 (referent) | ||||||||||
| PAV/AVI | 523 (46.6) | 393 (45.6) | 1.00 (0.80,1.25) | 0.990 | 0.963 | 183 (47.3) | 138 (47.6) | 1.15 (0.76,1.75) | 0.510 | 0.573 | 236 (46.3) | 170 (44.2) | 0.99 (0.73,1.34) | 0.924 | 0.893 | 104 (46.0) | 85 (45.5) | 0.64 (0.34,1.21) | 0.169 | 0.097 | 0.356 | 0.261 |
| PAV/PAV | 312 (27.8) | 258 (29.9) | 1.09 (0.84,1.40) | 0.427 | 0.446 | 122 (31.5) | 98 (33.8) | 1.19 (0.77,1.85) | 0.438 | 0.448 | 92 (18.0) | 85 (22.1) | 1.27 (0.87,1.86) | 0.215 | 0.155 | 98 (43.4) | 75 (40.1) | 0.60 (0.32,1.15) | 0.126 | 0.075 | ||
| Ptrend†† | 0.503 | 0.429 | Ptrend | 0.466 | 0.464 | Ptrend | 0.280 | 0.196 | Ptrend | 0.199 | 0.145 | |||||||||||
| TAS2R16 (rs846672) | ||||||||||||||||||||||
| CC | 497 (42.2) | 406 (44.6) | 1.00 (referent) | 110 (28.7) | 105 (36.2) | 1.00 (referent) | 268 (47.9) | 210 (49.2) | 1.00 (referent) | 119 (50.4) | 91 (47.1) | 1.00 (referent) | ||||||||||
| AC | 544 (46.1) | 379 (41.7) | 0.86 (0.71,1.04) | 0.116 | 0.132 | 197 (51.4) | 128 (44.1) | 0.69 (0.49,0.99) | 0.042 | 0.110 | 245 (43.8) | 164 (38.4) | 0.86 (0.65-1.13) | 0.268 | 0.226 | 102 (43.2) | 87 (45.1) | 1.09 (0.73-1.64) | 0.662 | 0.604 | 0.339 | 0.396 |
| AA | 138 (11.7) | 125 (13.7) | 1.12 (0.86,1.50) | 0.433 | 0.369 | 76 (19.9) | 57 (19.7) | 0.83 (0.53-1.29) | 0.398 | 0.671 | 47 (8.4) | 53 (12.4) | 1.38 (0.89-2.15) | 0.152 | 0.171 | 15 (6.4) | 15 (7.8) | 1.19 (0.55-2.59) | 0.664 | 0.707 | ||
| Ptrend | 0.948 | 0.955 | Ptrend | 0.250 | 0.484 | Ptrend | 0.618 | 0.684 | Ptrend | 0.581 | 0.573 | |||||||||||
| TAS2R50 (rs1376251) | ||||||||||||||||||||||
| TT | 347 (29.6) | 278 (30.6) | 1.00 (referent) | 224 (58.6) | 161 (55.5) | 1.00 (referent) | 48 (8.6) | 38 (8.9) | 1.00 (referent) | 75 (32.2) | 79 (40.7) | 1.00 (referent) | ||||||||||
| TC | 518 (44.2) | 405 (44.5) | 0.98 (0.78,1.23) | 0.854 | 0.960 | 139 (36.4) | 110 (37.9) | 1.13 (0.81,1.56) | 0.475 | 0.342 | 253 (45.4) | 209 (49.2) | 1.07 (0.67,1.70) | 0.795 | 0.725 | 126 (54.1) | 86 (44.3) | 0.66 (0.42,1.01) | 0.060 | 0.023 | 0.254 | 0.117 |
| CC | 307 (26.2) | 226 (24.9) | 0.90 (0.68,1.19) | 0.467 | 0.495 | 19 (5.0) | 19 (6.6) | 1.22 (0.62,2.40) | 0.566 | 0.285 | 256 (46.0) | 178 (41.9) | 0.90 (0.56,1.44) | 0.651 | 0.639 | 32 (13.7) | 29 (15.0) | 0.86 (0.47,1.57) | 0.621 | 0.543 | ||
| Ptrend | 0.471 | 0.503 | Ptrend | 0.401 | 0.192 | Ptrend | 0.324 | 0.273 | Ptrend | 0.294 | 0.200 | |||||||||||
P-values for all odds ratios and 95% confidence intervals were partially-adjusted for race (where appropriate), age, sex, screening site, endoscopic procedure and additionally, fully-adjusted for family history of colorectal cancer, vitamin supplement use, years of education, smoking status, pack-years of cigarette smoking, lifetime physical activity, and body mass index.
†
The p for interaction represents the significance of the gene-by-race/ethnicity interaction term from separate logistic regression analyses.
††
The p for trend is based on the score test for a variable assigned the dosage of the haplotype or variant allele